Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
11 January 2024 - 3:15AM
Zealand Pharma major shareholder announcement: Avoro Capital
Advisors LLC
Company announcement – No. 2 / 2024
Zealand Pharma major shareholder announcement: Avoro Capital
Advisors LLC
Copenhagen, Denmark, 10 January 2024 – Zealand
Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a
Copenhagen-based biotechnology company focused on the discovery and
development of innovative peptide-based medicines, today announces
the receipt on 9 January 2024 of notification pursuant to Section
38 of the Danish Capital Markets Act from Avoro Capital Advisors
LLC.
Following the private placement announced on 8 January 2024 in
Company announcement no. 1 / 2024, Avoro Life Sciences Fund LLC now
holds nominally 3,438,184 shares in Zealand Pharma A/S,
corresponding to 5.50% of the total share capital in Zealand Pharma
A/S. Avoro Capital Advisors LLC holds the corresponding number of
voting rights to the shares. The new shares will be admitted to
trading and official listing on Nasdaq Copenhagen A/S, in the ISIN
code for the existing shares, DK0060257814, following issuance,
expectedly on 15 January 2024.
Please see further details in the attached notification
forms.
# # #
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq:
ZEAL) ("Zealand") is a biotechnology company focused on the
discovery and development of peptide-based medicines. More than 10
drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. The company has
development partnerships with a number of blue-chip pharma
companies as well as commercial partnerships for its marketed
products.
Founded in 1998 and headquartered in Copenhagen, Denmark,
Zealand has a team in the U.S. For more information about Zealand’s
business and activities, please
visit http://www.zealandpharma.com.
Contact:
Adam Lange
(Investors) |
Investor Relations
Officer |
Zealand
Pharma |
alange@zealandpharma.com |
|
Anna Krassowska,
PhD (Investors and Media) |
Vice President,
Investor Relations & Corporate Communications |
Zealand
Pharma |
akrassowska@zealandpharma.com |
- Major shareholder template (Avoro Capital Advisors LLC)
(2)
- Major shareholder template (Avoro Life Sciences Fund) (1)
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Nov 2024 to Dec 2024
Zealand Pharma AS (TG:22Z)
Historical Stock Chart
From Dec 2023 to Dec 2024